Search

Reset

Status

Medical Condition

Displaying 1 - 3 of 3

Study to Test if BI 3802876 is Tolerated in People W/ Compensated Liver Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis

Condition: Liver Disease / MASH (formerly NASH)
Investigator: Julia Wattacheril, MD, MPH
Status: Currently Recruiting
The purpose of this research study is to determine how well BI3802876 is tolerated in people living with cirrhosis due to a liver condition called metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH). The study medication, BI3802876, is investigational, meaning it has not yet been approved by the United States Food and Drug…
Read More

A study to investigate the efficacy and safety of frexalimab versus tacrolimus in adults undergoing kidney transplantation

Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Currently Recruiting
This study is testing whether a new investigational medicine called frexalimab can safely and effectively prevent kidney transplant rejection compared to tacrolimus, a standard medication currently used after transplant. Participants will be randomly assigned to receive either frexalimab (given by injection every 4 weeks) or tacrolimus (taken as capsules…
Read More

VEL-101 (VELOXIS) to Prevent Rejection After Kidney Transplantation

Condition: Transplant / Kidney Transplant
Investigator: Lloyd Ratner, MD, MPH, FACS
Status: Currently Recruiting
The main goal of this clinical trial is to determine if an investigational medication called VEL101 is safe, well tolerated, and effective in people receiving a new kidney transplant. Participants will be randomly assigned to 2 different doses of VEL-101 or to tacrolimus, which is standardly used post-transplant to prevent rejection. Participants will be…
Read More